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0005 18. Present Status of Liver Transplantation * 
0006 T.E. Starzl, S. Iwatsuki, and B.W. Shaw Jr. 1 
0007 Historical Perspective 
0008 The concept of liver replacement was apparently first envisioned by Cannon 
0009 [1] of Los Angeles,who performed liver replacements in animals without surviv-
0010 al. His report was so brief that it did not have a title and did not even stipulate 
0011 the animals used. The first detailed report of liver transplantation was by C. 
0012 Stewart Welch [2] of Albany, New York, who transplanted auxiliary organs 
0013 into the pelvis or right paravertebral gutter of dogs. 
0014 The technical requirements of liver replacement and the behavior of dogs 
0015 submitted to this operation without immunosuppressive therapy were worked 
• 0016 out by ourselves [3, 4] and by the team headed by Francis D. Moore at the 
0017 Peter Bent Brigham Hospital in Boston [5]. The first chronic survivors after 
0018 liver replacement in experimental animals were obtained in 1963 and reported 
0019 in' 1965 [6]. These animals were treated with azathioprine alone, which could 
0020 often be stopped after only 3 or 4 months with prolonged subsequent good 
0021 health of the recipients <ilf mongrel nonrelated livers [7]. 
0022 The first clinical liver transplantations were performed in early 1963 [8]. 
0023 From this time until mid-1967 six attempts were made by us, all leading to 
0024 the death of the recipients within a few days or weeks. The first extended 
0025 survival after liver replacement in humans was achieved in the summer of 1967. 
0026 Our ~experience with the first 25 cases of liver replacement was summarized 
0027 in a book published in 1969 [7]. 
Including the first unsuccessful attempts, we had compiled 111 cases of 
orthotopic liver transplantation by the spring of 1976. Thirty-one of these 111 
patients lived for at least one postoperative year and from that original group 
the longest current survivor is now more than 12 years. It became apparent 
during this time [9] that many general aspects of care could be improved includ-
ing the technical details of the operation, diagnostic procedures during the post-
operative period (which were designed to identify causes other than rejection 
for postoperative hepatic failure), and immunosuppression. The basis for liver 
transplantation was strengthened by the introduction of modifications to allevi-
ate these sources of tragedy. The modifications included refined anatomical 
studies of the structures which had to be dealt with, increased application of 
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modern diagnostic techniques (including postoperative biopsies, and cholangio-
graphic studies), exploitation of microvascular techniques (particularly in pediat-
ric recipients), and use of methods which had become available for detection 
and classification of hepatitis. 
0049 At the same time, another development occurred in preservation which could 
0050 not be fully exploited because of other limitations, especially that of suboptimal 
0051 immunosuppression. Bel]ichou et a1. [10] in our laboratories, and the group 
0052 at Cambridge [11] described techniques for cold preservation of the liver after 
0053 infusion of special solutions. These permitted the preservation in "slush" of 
0054 animal livers for as long as 12 to 24 h. A bottleneck was thus broken, permitting 
0055 harvesting of human livers in distant cities and their transportation to the site 
0056 of the recipient operation. Previously it was necessary to have the donor and 
0057 recipient in the same city, and preferably in the same hospital. 
0058 In the mid 1970s it appeared at first that a substantial improvement would 
0059 be possible by refinements of surgical, medical, and immunosuppressive tech-
0060 niques that were already available. The 1-year survival rate in a series of 30 
0061 consecutive patients rose to 50% [12]. However, in a subsequent series of 30 
0062 patients the survival dipped again to a level only slightly better than in the 
0063 first cases [13, 14]. Our conclusion was that some fundamental improvement 
0064 would be necessary in immunosuppression before the full potential of liver 
0065 transplantation could be realized. 
0066 This improvement was made possible by the introduction of cyclosporin 
0067 A, an extract of two fungi, which was discovered and studied by Borel and 
0068 his associates and Basel Switzerland [15, 16]. 
0069 The first clinical trials of cyclosporin A were made in England by CaIne 
0070 and ,his associates [17, 18] at Cambridge and by Powles et a1. [19] at the Royal 
0071 Marsden Hospital, also in England. CaIne's trials were for whole organ trans-
0072 plantation and Powles worked with bone marrow transplantation. In the United 
0073 States, cyclosporin A became available in late 1979. Its combination with low 
0074 dose steroids was advocated and standardized by our group [20, 21], working 
0075 in renal transplantation. The optimal use of cyclosporin A required the coinci-
0076 dent administration of steroids, but the amounts of prednisone and/or hydrocor-
0077 tisone were a fraction of those previously required. In March 1980, after having 
0078 developed considerable experience with cadaveric renal transplantation, we un-
0079 dertook the first cyclosporin trials in liver transplantation. The results, as de-
0080 scribed below, have revolutionized the expectations after liver transplantation 
0081 [14, 22]. 
0082 Assessment of the Precyclosporin A Era 
0083 During the first years of our experience, detailed and finally repetitive analyses 
0084 of the causes for failure were publishedl including delineation of the complex 
0085 infectious patterns seen postoperatively. The high mortality was due principally 
0086 to the lack of effectiveness of conventional immunosuppression by azathioprine, 
0087 prednisone, and ALG. The vitality of efforts at liver transplantation was main-
OOH8 tained mainly by the realization that many of the survivors enjoyed a high 
0089 quality of life, especially beyond 1 year after transplantation. 
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Table 1. Indications for transplantation in the 
precyclosporin A era, 1963-1979 (adults- 19 to 
70 years) 
Chronic aggressive hepatitis 
Primary liver malignancy 
Alcoholic cirrhosis 
Primary biliary cirrhosis 
Sclerosing cholangitis 
Secondary biliary cirrhosis 
Massive hepatic necrosis (B virus) 
Budd-Chiari syndrome 
Protoporphyria 
33 
16 
16 
7 
6 
3 
1 
1 
84 
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Table 2. Indications for transplantation in the 
precyc1osporin Aery, 1963-1979 E~1U years) 
Biliary atresia 
Inborn metabolic errors 
Chronic aggressive hepatitis 
Hepatoma 
Neonatal hepatitis 
Congenital biliary cirrhosis 
Congenital hepatic fibrosis 
Secondary biliary cirrhosis 
a Inborn errors of metabolism 
Alpha-I-antitrypsin deficiency 
Wilson's disease 
Tyrosinerrtl! 
Type IV glycogen storage disease 
53 
13" 
13 
3 
2 
1 
1 
-.1 
87 
9 
2 
0090 In 1978 and 1979 it was hoped that the safety and efficacy of standard 
0091 immunosuppression could be improved with the adjuvant use of thoracic duct 
0092 4rainage [23]. However, patients with end-stage liver disease almost always 
0093 'had ascites, and probably because of this the drainage collected through the 
0094 thoracic duct was so voluminous that preoperative lymphoid depletion with 
0095 this technique proved hazardous. Some patients prepared with thoracic duct 
0096 drainage produced as much as 2 liters per hour in the preoperative period, 
0097 making fluid and blood volume management a near impossibility. It became 
0098 obvious that thoracic duct drainage could be,applied sparingly if at all to pro-
0099 spective liver recipients [13]. 
0100 By the end of 1979, 171 patients had been treated with liver transplantation 
0101 over a period of 16 years; of these, 84 were adults (Table 1). 
0103 During the same years 87 pediatric patients (18 years or younger) were 
0104 also treated (Table 2), 
0106 These 171 recipients were divided into three consecutive groups. The first 
0107 111 were treated between 1963 and 1976, and of these 31 (28%) lived for as 
0108 long as 1 year. In a second wave of 30 patients, the 1-year survival increased 
0109 to 50%, but in a subsequent further sample of 30 the 1-year survival declined 
0110 again to a level almost as low as in the original series (Fig. 1), 
0111 The Cyclosporin A Era 
0112 By the end of 1979 our first and profoundly encouraging experience was being 
0113 obtained with cadaveric renal transplantation under cyclosporin A and steroids. 
0114 It was natural and justifiable to extend this new form of therapy almost immedi-
0115 ately to liver recipients in view of the poor survival obtained with livers in 
0116 the past. After 22 cadaveric kidney transplantations had been performed, the 
first liver recipients were treated in early 1980. The results have already shown 
a profound influence upon survival in liver transplantation. In the first group 
of 14 patients entered for consideration for cyclosporin A therapy in Denver, 
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0082 Fig. 1. Survival in three consecutive series of orthotopic liver recipients treated over a 16-year period. 
0083 Note that a second group of 30 patients enjoyed a higher survival rate than patients in the first 
0084 series, but that these gains could not be maintained in a third series 
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0086 Fig. 2. Denver liver transplant series, cyclosporin A vs. conventional treatment. (New England Journal 
0087 of Medicine 305:266--269,1981) 
two died on the operating table and could not be treated with any kind of 
immunosuppression. Of the 12 who survived operation, 11 (92%) lived out 
the first postoperative year [22]. These recipients enjoyed a greater freedom 
from irreversible rejection than had ever been seen before, and the steroid re-
quirements to meet this objective were a fraction of those in our historical 
experience. The combined historical life survival curves with conventional im-
munosuppression compared to those achieved with cyclosporin A and low dose 
steroids are shown in Fig. 2. 
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Table 3. The Pittsburgh experience with liver replacement 
Number 
26 
17 
Dead 
1981 8 
1982 2 3 
Alive 
18 (69.2%) 
15 (88.2%) 
3 These deaths were in paticnts with hypoplastic or absent portal veins 
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Table 4. Diagnoses in 57 patients· treated in the cyclosporin A era (1980-1982); 
five patients had two diagnoses 
Chronic aggressive hepatitis 
Hepatic neoplasm 
Alpha-I-antitrypsin disease 
Biliary atresia 
Sclerosing cholangitis 
Primary biliary cirrhosis 
Budd-Chiari syndrome 
Choledochal cyst and biliary cirrhosis 
Hepatic fibrosis (Byler's) 
Secondary biliary cirrhosis (trauma) 
Caroli's disease 
Neonatal hepatitis 
Sea blue histiocyte syndrome 
Subacute Wilson's disease 
Type I glycogen storage disease 
Tyrosinemia 
14 
10 
8b 
7 
4 
4 
3 
2 
2 
2 
1 
a Two thirds of the recipients were adults, one third were children 
b Inborn errors of metabolism 
The liver transplantation team moved to the University Health Center of 
Pittsburgh on 1 January J981. The first four patients treated in this new environ-
ment died, all as a direct consequence of transplanting poorly preserved organs. 
Analysis of these tragic events showed that the procurement techniques which 
were slightly different in the Eastern center had not fit perfectly with those 
used in the Colorado program. The problems were rectified. Of the next 22 
recipients 18 are still living after 4 months to a year. The only four deaths 
amongst the last 22 patients were caused by: a biliary tract leak leading to 
0136 a subhepatic abscess and rupture of the portal vein, systemic infection with 
0137 aspergillus, failure in a patient with preexisting massive right to left V -A shunts 
om to have these shunts close postoperatively, and development of a hepatic artery 
0139 fistula into the reconstructed common duct. The Pittsburgh results are summa-
0140 rized in Table 3. 
0142 The diagnoses in all patients treated in the cyclosporin A era are summarized 
0143 in Table 4. • 
0145 In pediatric recipients, the great advantage of treatment with cyclosporin 
0146 A and low doses of steroids has been apparent in the rapid and seemingly 
0147 normal growth of infants and children in this series [24]. 
----------------------------------~------
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0148 Auxiliary Liver Transplantation 
0149 The alternative to orthotopic liver transph,mtation (liver replacement) is the 
0150 transplantation of an extra liver (auxiliary transplantation) without removal 
0151 of the diseased native organ. Clinical trials with this approach have been pro-
0152 foundly discouraging, as summarized to the autumn of 1978 by Fortner et al. 
[25] from the compiled world experience. Of nearly 50 well-documented auxilia-
ry transplantations, only one could be pronounced an unequivocal success. 
0155 Subsequently a report from Paris has described a second success [26]. 
0156 Our opinion has been that auxiliary liver transplantation should be restricted 
0157 to patients with potentially reversible liver disease. In such a situation, the 
0158 extra liver could be construed as a temporary support organ that could be 
0159 later removed. However, we have encountered increasing numbers of patients 
0160 whose portal vein has clotted in the hepatic hilum, making it technically impossi-
0161 ble to consider liver replacement. Such patients could theoretically be helped 
0162 by an auxiliary liver transplantation, particularly when the superior mesenteric 
0163 vein or other distal tributories to the main portal circulation are still open. 
0164 In earlier work in our laboratories, it was shown that the optimal conditions 
0165 for vascularization of an auxiliary liver graft required input from the portal 
0166 circulation [27], largely because of the high concentrations of endogenous hor-
0167 mones that are to be found in this venous blood. These experiments, which 
0168 eventually resulted in an interesting new field of hepatology (termed hepata-
0169 trophic physiology), have been summarized elsewhere [28]. 
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